Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Ex Vivo Expansion of Hematopoietic Stem Cells for Therapeutic Purposes: Lessons from Development and the Niche.

Tajer P, Pike-Overzet K, Arias S, Havenga M, Staal FJT.

Cells. 2019 Feb 18;8(2). pii: E169. doi: 10.3390/cells8020169. Review.

2.

Nine draft genome sequences of Claviceps purpurea s.lat., including C. arundinis, C. humidiphila, and C. cf. spartinae, pseudomolecules for the pitch canker pathogen Fusarium circinatum, draft genome of Davidsoniella eucalypti, Grosmannia galeiformis, Quambalaria eucalypti, and Teratosphaeria destructans.

Wingfield BD, Liu M, Nguyen HDT, Lane FA, Morgan SW, De Vos L, Wilken PM, Duong TA, Aylward J, Coetzee MPA, Dadej K, De Beer ZW, Findlay W, Havenga M, Kolařík M, Menzies JG, Naidoo K, Pochopski O, Shoukouhi P, Santana QC, Seifert KA, Soal N, Steenkamp ET, Tatham CT, van der Nest MA, Wingfield MJ.

IMA Fungus. 2018 Jul;9:401-418. doi: 10.5598/imafungus.2018.09.02.10. Epub 2018 Dec 14.

3.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1.

Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH.

PLoS One. 2018 Nov 14;13(11):e0205139. doi: 10.1371/journal.pone.0205139. eCollection 2018.

4.

Enhancing viral vaccine production using engineered knockout vero cell lines - A second look.

Hoeksema F, Karpilow J, Luitjens A, Lagerwerf F, Havenga M, Groothuizen M, Gillissen G, Lemckert AAC, Jiang B, Tripp RA, Yallop C.

Vaccine. 2018 Apr 12;36(16):2093-2103. doi: 10.1016/j.vaccine.2018.03.010. Epub 2018 Mar 16.

5.

Firewalls Prevent Systemic Dissemination of Vectors Derived from Human Adenovirus Type 5 and Suppress Production of Transgene-Encoded Antigen in a Murine Model of Oral Vaccination.

Revaud J, Unterfinger Y, Rol N, Suleman M, Shaw J, Galea S, Gavard F, Lacour SA, Coulpier M, Versillé N, Havenga M, Klonjkowski B, Zanella G, Biacchesi S, Cordonnier N, Corthésy B, Ben Arous J, Richardson JP.

Front Cell Infect Microbiol. 2018 Jan 25;8:6. doi: 10.3389/fcimb.2018.00006. eCollection 2018.

6.

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.

Abbink P, Kirilova M, Boyd M, Mercado N, Li Z, Nityanandam R, Nanayakkara O, Peterson R, Larocca RA, Aid M, Tartaglia L, Mutetwa T, Blass E, Jetton D, Maxfield LF, Borducchi EN, Badamchi-Zadeh A, Handley S, Zhao G, Virgin HW, Havenga MJ, Barouch DH.

J Virol. 2018 Feb 26;92(6). pii: e01924-17. doi: 10.1128/JVI.01924-17. Print 2018 Mar 15.

7.

Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56.

Duffy MR, Alonso-Padilla J, John L, Chandra N, Khan S, Ballmann MZ, Lipiec A, Heemskerk E, Custers J, Arnberg N, Havenga M, Baker AH, Lemckert A.

J Gen Virol. 2018 Jan;99(1):135-147. doi: 10.1099/jgv.0.000978. Epub 2017 Nov 20.

PMID:
29154744
8.

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Alonso-Padilla J, Papp T, Kaján GL, Benkő M, Havenga M, Lemckert A, Harrach B, Baker AH.

Mol Ther. 2016 Feb;24(1):6-16. doi: 10.1038/mt.2015.194. Epub 2015 Oct 19. Review.

9.

Painless nodule on the external ear.

Phipps K, Havenga M, Midgen C, Bezuhly M.

Pediatr Dermatol. 2015 May-Jun;32(3):417-8. doi: 10.1111/pde.12503. No abstract available.

PMID:
25996673
10.

Challenges in manufacturing adenoviral vectors for global vaccine product deployment.

Vellinga J, Smith JP, Lipiec A, Majhen D, Lemckert A, van Ooij M, Ives P, Yallop C, Custers J, Havenga M.

Hum Gene Ther. 2014 Apr;25(4):318-27. doi: 10.1089/hum.2014.007. Epub 2014 Apr 2. Review.

PMID:
24593243
11.

Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection.

Trinh HV, Lesage G, Chennamparampil V, Vollenweider B, Burckhardt CJ, Schauer S, Havenga M, Greber UF, Hemmi S.

J Virol. 2012 Feb;86(3):1623-37. doi: 10.1128/JVI.06181-11. Epub 2011 Nov 30.

12.

Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35.

Kälin S, Amstutz B, Gastaldelli M, Wolfrum N, Boucke K, Havenga M, DiGennaro F, Liska N, Hemmi S, Greber UF.

J Virol. 2010 May;84(10):5336-50. doi: 10.1128/JVI.02494-09. Epub 2010 Mar 17.

13.

Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs.

Hartgroves LC, Koudstaal W, McLeod C, Moncorgé O, Thompson CI, Ellis J, Bull C, Havenga MJ, Goudsmit J, Barclay WS.

Vaccine. 2010 Apr 9;28(17):2973-9. doi: 10.1016/j.vaccine.2010.02.012. Epub 2010 Feb 25.

PMID:
20188682
14.

Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

Koudstaal W, Hartgroves L, Havenga M, Legastelois I, Ophorst C, Sieuwerts M, Zuijdgeest D, Vogels R, Custers J, de Boer-Luijtze E, de Leeuw O, Cornelissen L, Goudsmit J, Barclay W.

Vaccine. 2009 Apr 28;27(19):2588-93. doi: 10.1016/j.vaccine.2009.02.033. Epub 2009 Feb 20.

PMID:
19428865
15.

Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Adams WC, Bond E, Havenga MJ, Holterman L, Goudsmit J, Karlsson Hedestam GB, Koup RA, Loré K.

J Gen Virol. 2009 Jul;90(Pt 7):1600-10. doi: 10.1099/vir.0.008342-0. Epub 2009 Mar 12.

PMID:
19282435
16.

Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma.

Kuhlmann KF, van Geer MA, Bakker CT, Dekker JE, Havenga MJ, Elferink RP, Gouma DJ, Bosma PJ, Wesseling JG.

Cancer Gene Ther. 2009 Jul;16(7):585-97. doi: 10.1038/cgt.2009.4. Epub 2009 Jan 30.

PMID:
19180144
17.

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH.

Nature. 2009 Jan 1;457(7225):87-91. doi: 10.1038/nature07469. Epub 2008 Nov 9.

18.

Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer.

Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, Goudsmit J, McVey JH, Nicklin SA, Baker AH.

J Virol. 2009 Jan;83(1):479-83. doi: 10.1128/JVI.01878-08. Epub 2008 Oct 22.

19.

Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination.

Kaufman DR, Liu J, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.

J Immunol. 2008 Sep 15;181(6):4188-98.

20.

Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.

Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J.

Biotechnol Bioeng. 2008 Jun 1;100(2):273-83. doi: 10.1002/bit.21757.

PMID:
18512821
21.

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.

J Virol. 2008 Jul;82(14):6829-37. doi: 10.1128/JVI.00353-08. Epub 2008 Apr 30.

22.

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.

Liu J, Ewald BA, Lynch DM, Denholtz M, Abbink P, Lemckert AA, Carville A, Mansfield KG, Havenga MJ, Goudsmit J, Barouch DH.

J Virol. 2008 May;82(10):4844-52. doi: 10.1128/JVI.02616-07. Epub 2008 Mar 12.

23.

Adenovirus serotype 5 hexon mediates liver gene transfer.

Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH.

Cell. 2008 Feb 8;132(3):397-409. doi: 10.1016/j.cell.2008.01.016.

24.

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K.

Infect Immun. 2008 Apr;76(4):1709-18. doi: 10.1128/IAI.01614-07. Epub 2008 Jan 22.

25.

Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine.

Samina I, Havenga M, Koudstaal W, Khinich Y, Koldijk M, Malkinson M, Simanov M, Perl S, Gijsbers L, Weverling GJ, Uytdehaag F, Goudsmit J.

Vaccine. 2007 Nov 28;25(49):8338-45. Epub 2007 Oct 15.

PMID:
17977629
26.

Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor.

Fleischli C, Sirena D, Lesage G, Havenga MJ, Cattaneo R, Greber UF, Hemmi S.

J Gen Virol. 2007 Nov;88(Pt 11):2925-34.

27.

High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector.

Vogels R, Zuijdgeest D, van Meerendonk M, Companjen A, Gillissen G, Sijtsma J, Melis I, Holterman L, Radosevic K, Goudsmit J, Havenga MJ.

J Gen Virol. 2007 Nov;88(Pt 11):2915-24.

PMID:
17947512
28.

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.

Ophorst OJ, Radosević K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, van Ooij MJ, Holterman L, Companjen A, Goudsmit J, Havenga MJ.

Vaccine. 2007 Aug 29;25(35):6501-10. Epub 2007 Jun 29.

PMID:
17646036
29.

Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Loré K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA.

J Immunol. 2007 Aug 1;179(3):1721-9.

30.

Targeting of adenovirus serotype 5 (Ad5) and 5/47 pseudotyped vectors in vivo: fundamental involvement of coagulation factors and redundancy of CAR binding by Ad5.

Waddington SN, Parker AL, Havenga M, Nicklin SA, Buckley SM, McVey JH, Baker AH.

J Virol. 2007 Sep;81(17):9568-71. Epub 2007 Jun 6.

31.

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J.

Infect Immun. 2007 Aug;75(8):4105-15. Epub 2007 May 25.

32.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63. Epub 2007 Feb 28.

33.

Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D.

Parker AL, McVey JH, Doctor JH, Lopez-Franco O, Waddington SN, Havenga MJ, Nicklin SA, Baker AH.

J Virol. 2007 Apr;81(7):3627-31. Epub 2007 Jan 24.

34.

A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cells.

Marzio G, Kerkvliet E, Bogaards JA, Koelewijn S, De Groot A, Gijsbers L, Weverling GJ, Vogels R, Havenga M, Custers J, Pau MG, Guichoux JY, Lewis J, Goudsmit J.

Vaccine. 2007 Mar 8;25(12):2228-37. Epub 2006 Dec 28.

PMID:
17250936
35.

Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence.

Ophorst OJ, Radosević K, Ouwehand K, van Beem W, Mintardjo R, Sijtsma J, Kaspers J, Companjen A, Holterman L, Goudsmit J, Havenga MJ.

Vaccine. 2007 Feb 9;25(8):1426-36. Epub 2006 Nov 7.

PMID:
17161889
36.

Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.

Brouwer E, Havenga MJ, Ophorst O, de Leeuw B, Gijsbers L, Gillissen G, Hoeben RC, ter Horst M, Nanda D, Dirven C, Avezaat CJ, Goudsmit J, Sillevis Smitt P.

Cancer Gene Ther. 2007 Feb;14(2):211-9. Epub 2006 Nov 3.

PMID:
17082793
37.

Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.

Thorner AR, Lemckert AA, Goudsmit J, Lynch DM, Ewald BA, Denholtz M, Havenga MJ, Barouch DH.

J Virol. 2006 Dec;80(24):12009-16. Epub 2006 Oct 11.

38.

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH.

J Clin Microbiol. 2006 Oct;44(10):3781-3.

39.

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.

Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ.

J Gen Virol. 2006 Oct;87(Pt 10):2891-9.

PMID:
16963747
40.

Human CD4+ T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus.

Veltrop-Duits LA, Heemskerk B, Sombroek CC, van Vreeswijk T, Gubbels S, Toes RE, Melief CJ, Franken KL, Havenga M, van Tol MJ, Schilham MW.

Eur J Immunol. 2006 Sep;36(9):2410-23.

41.

Viral vectors for malaria vaccine development.

Li S, Locke E, Bruder J, Clarke D, Doolan DL, Havenga MJ, Hill AV, Liljestrom P, Monath TP, Naim HY, Ockenhouse C, Tang DC, Van Kampen KR, Viret JF, Zavala F, Dubovsky F.

Vaccine. 2007 Mar 30;25(14):2567-74. Epub 2006 Aug 1. Review.

PMID:
16914237
42.

Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells.

de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed SM, Radosevic K, Havenga MJ, Scheper RJ.

J Immunol. 2006 Aug 15;177(4):2208-15.

43.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

PMID:
16847108
44.

Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.

van Leeuwen EB, Cloosen S, Senden-Gijsbers BL, Agervig Tarp M, Mandel U, Clausen H, Havenga MJ, Duffour MT, García-Vallejo JJ, Germeraad WT, Bos GM.

Cytotherapy. 2006;8(1):24-35.

PMID:
16627342
45.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.

Nature. 2006 May 11;441(7090):239-43. Epub 2006 Apr 16.

PMID:
16625206
46.

Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers.

Lecollinet S, Gavard F, Havenga MJ, Spiller OB, Lemckert A, Goudsmit J, Eloit M, Richardson J.

J Virol. 2006 Mar;80(6):2747-59.

47.

Human CD46-transgenic mice in studies involving replication-incompetent adenoviral type 35 vectors.

Verhaagh S, de Jong E, Goudsmit J, Lecollinet S, Gillissen G, de Vries M, van Leuven K, Que I, Ouwehand K, Mintardjo R, Weverling GJ, Radosevic K, Richardson J, Eloit M, Lowik C, Quax P, Havenga M.

J Gen Virol. 2006 Feb;87(Pt 2):255-65.

PMID:
16432010
48.

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M.

Infect Immun. 2006 Jan;74(1):313-20.

49.

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.

Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH.

J Virol. 2005 Nov;79(22):14161-8.

50.

Prospects for chimeric adenoviruses.

Havenga MJ, Vogels R, Bout A.

IDrugs. 2001 Feb;4(2):179-88. No abstract available.

PMID:
16032480

Supplemental Content

Loading ...
Support Center